Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
International Urology and Nephrology|June 4, 2023
Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitorsImmanuel Augustin Oppolzer, Josef Riester, Roland Büttner, et al.
Urologia Internationalis|December 11, 2025
Outpatient vs. Inpatient Ureterorenoscopy - A Retrospective Dual-Center AnalysisMaximilian Reinhard Müller, Marco Julius Schnabel, Immanuel Augustin Oppolzer, et al.
Urologia Internationalis|April 16, 2024
Ureterorenoscopic Stone Removal without Antibiotic ProphylaxisMaximilian Reinhard Müller, Eva-Maria Prey, Philipp Julian Spachmann, et al.
Urologia Internationalis|October 3, 2024
Antibiotic Prophylaxis of Transrectal Biopsy of the Prostate: A Plea for FosfomycinPhilipp Julian Spachmann, Daniel Witt, Johannes Breyer, et al.
European Urology|September 30, 2025
CaboPoint: A Phase 2 Study of Second-line Cabozantinib After Checkpoint Inhibitor-based Combination Therapy in Patients with Metastatic Renal Cell CarcinomaLaurence Albiges, Thomas Powles, Anand Sharma, et al.
World Journal of Urology|August 12, 2024
Prostate-specific membrane antigen-radioguided surgery salvage lymph node dissection: experience with fifty oligorecurrent prostate cancer patientsRoman Mayr, Simon Udo Engelmann, Yushan Yang, et al.
Cancers|September 14, 2024
Cabozantinib Plus Nivolumab in Adult Patients with Advanced or Metastatic Renal Cell Carcinoma: A Retrospective, Non-Interventional Study in a Real-World Cohort/GUARDIANS ProjectThomas Hilser, Christopher Darr, Günter Niegisch, et al.
World Journal of Urology|March 23, 2020
Radiation exposure during retrograde intrarenal surgery (RIRS): a prospective multicenter evaluationSimon Hein, Konrad Wilhelm, Arkadiusz Miernik, et al.
European Urology Open Science|July 23, 2025
Real-world Evidence from a Retrospective Multicentre Analysis on First-line Therapy for Metastatic Papillary Renal Cell Carcinoma. A GUARDIANS ProjectThomas Hilser, Jozefina Casuscelli, Can Aydogdu, et al.
Cancer Immunology, Immunotherapy : CII|July 12, 2026
Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS)Stefanie Zschäbitz, Irfan Bhatti, Jozefina Casuscelli, et al.
Pageof 1